High prevalence of cardiovascular risk factors in Durban South African Indians: The Phoenix Lifestyle Project

D R Prakashchandra, T M Esterhuizen, A A Motala, P Gathiram, D P Naidoo

Background. Previous studies show a high prevalence of cardiovascular (CV) risk factors in South African (SA) Asian Indians, with the emergence of premature coronary artery disease in young Indian subjects.

Objective. To determine the prevalence of CV risk factors in this population.

Methods. This was a cross-sectional study of randomly selected adults aged 15 - 64 years from the suburb of Phoenix in Durban, KwaZulu-Natal Province, SA. All participants had demographic, anthropometric and biochemical measurements using the modified World Health Organization (WHO) STEPwise survey methods. Hypertension, obesity, lipid abnormalities and diabetes mellitus (DM) were diagnosed using WHO criteria. Age-standardised frequencies for glycaemic indices were calculated according to the WHO standard world population distribution.

Results. Of the 1 428 subjects who responded (response rate 72.1%), complete data for analysis were available on 1 378 (1 001 women). The mean age was 45.5 (standard deviation 13) years. There were high prevalences of hypertension (47.5%), DM (20.1%), total body obesity (raised body mass index) (32.4%) and increased waist circumference (73.1%). The 'thin-fat' Asian phenotype (isolated abdominal obesity) was found in only 4.8% of participants. High prevalences of total body obesity (32.1%), increased waist circumference (31.3%) and insulin resistance (28.2%) were documented in the youngest age group. Over half of the males and 14.6% of females were current smokers. Diabetic dyslipidaemia was found in 61 subjects (4.4%). In multivariate analysis, age, triglycerides and waist circumference measurement were significant independent risk factors associated with DM and, together with fasting glucose, also predicted hypertension.

Conclusion. Compared with Asian Indian subjects with similar environmental exposure in previous studies, the magnitude of change in risk factor prevalence over the past two decades has been of epidemic proportions.


The latest data from the International Diabetes Federation[11] show that the prevalence of adults with type 2 diabetes mellitus (DM) is highest in low- and middle-income countries, with sub-Saharan Africa and the Indian subcontinent being highlighted as two of the regions where this rise will be the greatest. Earlier epidemiological studies[12,13] show that South African (SA) Indians have a high prevalence[12] and incidence[13] of DM. In the past two decades there have been major sociopolitical changes in these communities, and the lack of current data on the changes in cardiovascular (CV) risk profile and the emergence of premature coronary artery disease[14] was the rationale for a survey of the CV risk factor profile of SA Indians.

Objective
To determine the CV risk factor prevalence in a community-based sample of SA Indians.

Methods
Sampling
The Phoenix Lifestyle Project was a cross-sectional study conducted over a 2-year period (January 2007 - December 2008) on SA Indians aged 15 - 64 years residing in the Phoenix area (eThekwini Municipality, Durban, SA). This community forms a heterogeneous population of Dravidian and Aryan ancestry, and are mainly descendants of Indians who arrived in SA from 1860 as indentured labourers on the sugar plantations in Natal.[15]

Two-stage cluster sampling was used to select the households. First, a proportional representation of the number of households was selected from each area. Thereafter, the households to be studied in each area were randomly selected. One individual from each household was selected using the Kish method.[11] Fieldworkers were trained to follow a prescribed guideline using the Kish method of selection so that participants were stratified for age (15 - 24, 25 - 34, 35 - 44, 45 - 54 and 55 - 64 years) and gender (male and female), with 198 males and 198 females in each stratum.

Ethical considerations
The study was approved by the University of KwaZulu-Natal Bioethics Committee (ethics reference: E336/05) and conformed to the principles in the Declaration of Helsinki. All subjects gave written informed consent for the collection of the data and were informed of the results of the examinations undertaken. Subjects in whom risk factors were identified were referred to a health facility for further evaluation and management.
Data collection
The World Health Organization (WHO) modified STEPS questionnaire for non-communicable disease risk factors (version 1.4 questionnaire) was used to record the demographic (including age, sex, education and income level) information and behavioural measurements at the participants’ homes. Other information included type of diet, physical activity, smoking habits, alcohol consumption and a personal and family (first-degree relatives) history of DM, hypertension and CV risk factors.

The clinical examination and investigations were performed at the Lifestyle Centre, Inkosi Albert Luthuli Central Hospital, Durban. Anthropometric measurements performed included height, weight and waist circumference according to WHO criteria. Venous blood samples were taken after an overnight fast for measurement of plasma glucose, serum insulin and serum lipid (total cholesterol, high-density lipoprotein (HDL) cholesterol and total triglyceride) levels. Fasting plasma glucose was measured using the glucose oxidase method and plasma insulin was measured by immunoassay. A 75 g oral glucose tolerance test (OGTT) was performed on participants who did not self-report a positive history of DM, for fasting and 2-hour plasma glucose levels. Blood pressure (BP) was recorded on three occasions at 2-minute intervals and the average of the three readings was documented.

Definition and classification of CV risk factors

Anthropometry
Based on the body mass index (BMI), participants were classified as of normal weight (18.50 - 24.99 kg/m²), overweight (≥25 - 29.99 kg/m²) or obese (≥30 kg/m²). The revised cut-off point for Asian Indians was also applied, i.e. subjects with a BMI <23 kg/m² were classified as normal, those with a BMI of 23.0 - 24.9 kg/m² as overweight and those with a BMI of ≥25.0 kg/m² as obese. The prevalence of the ‘thin-fat Asian phenotype’ was also determined in subjects with isolated abdominal obesity, i.e. Asian criteria for waist circumference (men >90 cm, women >80 cm) and a normal BMI (<23 kg/m²).

Hypertension
Individuals who self-reported previously diagnosed hypertension, and/or those with blood pressure readings ≥140 and ≥90 mmHg (average of three readings) (Joint National Committee VII (JNC VII) criteria) and/or those on current antihypertensive therapy were defined as having systemic hypertension. Using JNC VII guidelines, individuals with a systolic blood pressure of 120 - 139 mmHg or a diastolic blood pressure of 80 - 89 mmHg were classified as having prehypertension.

Biochemistry
Lipid parameters were classified using criteria of the National Cholesterol Adult Panel III guidelines: serum total cholesterol ≥5.17 mmol/L, serum total triglyceride ≥1.69 mmol/L, HDL cholesterol <1.04 mmol/L (men) and <1.29 mmol/L (women), and low-density lipoprotein (LDL) cholesterol ≥2.59 mmol/L. LDL cholesterol was calculated using the Friedewald equation. Diabetic dyslipidaemia was diagnosed if raised levels of LDL cholesterol and triglycerides, as well as low levels of HDL cholesterol, were present.

The WHO criteria were used to classify glycaemic categories based on fasting plasma glucose (FPG): DM if the FPG was ≥7.0 mmol/L, and impaired fasting glucose (IFG) if the FPG was ≥6.1 and <7.0 mmol/L. Impaired glucose tolerance was defined if the FPG was <7.0 mmol/L and the 2-hour plasma glucose level during the OGTT was ≥7.8 and <11.1 mmol/L. Subjects with IFG or IGT were classified as having prediabetes. Homeostatic model assessment for insulin resistance (HOMA-IR) values were calculated using the formula: fasting insulin (µU/mL) × fasting glucose (mmol/L)/22.5. Insulin resistance was defined as a HOMA-IR value of ≥2.6. The age-standardised frequencies for glycaemic indices were calculated according to the WHO standard world population distribution.

Statistical analysis
Statistical analysis was performed using the SPSS programme (version 22, SPSS, USA). The distributional properties for all variables were investigated, and variables with a skewed distribution were log-transformed or analysed using non-parametric testing. Means and standard deviations (SDs) and median values with interquartile ranges for non-Gaussian distributed variables were calculated for continuous variables. Categorical data were presented as percentages with corresponding 95% confidence intervals (CIs); the χ² test was used for intergroup comparisons. For continuous variables, analysis of variance was used. Post-hoc analysis of variance comparisons for continuous variables was based on the Bonferroni correction.

Logistic regression (stepwise, backward) was used to identify risk factors associated with DM and hypertension. A p-value of <0.05 was regarded as being statistically significant.

Results
Of 1 980 participants selected, 1 428 individuals (402 males, 1 026 females) participated in the study, giving a response rate of 72.1%. Non-responders were mainly males (40.6%, 402/990 male participants selected), with participation being higher in the older age groups. Complete data on all variables were available on 1 378 participants, who formed the study group for further analysis shown in Table 1. The majority of respondents were women (n=1 001, 72.6%), under-represented in the 15 - 34-year age groups and over-represented in the 35 - 64-year age groups (Table 1).

The mean age of the total sample was 45.5 (SD 13) years, with the highest proportion of subjects in the 45 - 54-year age group (30.7%) (Table 2). The general pattern for blood pressure and biochemical variables among both males and females was an increase with advancing age. Participants in all age groups reported a positive family history for one or more of the following conditions: obesity, DM, hypertension, myocardial infarction (MI), stroke and heart failure (congestive heart failure (CHF), with hypertension being the most frequently reported (71.2%).

CV and metabolic risk factors in the sample
The most frequent abnormality was adiposity, both total (BMI) and central obesity (waist circumference) (Table 3). Almost one-third were classified as obese (32.4%) or overweight (32.0%), with the prevalence increasing with age (p-trend <0.001). Using Asian cut-points, the prevalence of obesity doubled to 64.5%, and was significantly higher in women (71.0%) than in men (44.5%)

<table>
<thead>
<tr>
<th>Age group (years)</th>
<th>Total, n (%)</th>
<th>Males, n (%)</th>
<th>Females, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 - 24</td>
<td>131 (9.5)</td>
<td>54 (41.2)</td>
<td>77 (58.8)</td>
</tr>
<tr>
<td>25 - 34</td>
<td>161 (11.6)</td>
<td>60 (37.3)</td>
<td>101 (62.7)</td>
</tr>
<tr>
<td>35 - 44</td>
<td>295 (21.4)</td>
<td>68 (23.1)</td>
<td>227 (76.9)</td>
</tr>
<tr>
<td>45 - 54</td>
<td>423 (30.7)</td>
<td>81 (20.1)</td>
<td>342 (79.9)</td>
</tr>
<tr>
<td>55 - 64</td>
<td>368 (26.7)</td>
<td>114 (30.9)</td>
<td>254 (69.0)</td>
</tr>
<tr>
<td>Total</td>
<td>1 378</td>
<td>377 (27.3)</td>
<td>1 001 (72.6)</td>
</tr>
</tbody>
</table>
Table 2. Demographic and clinical characteristics of participants

<table>
<thead>
<tr>
<th></th>
<th>Age (years), mean (SD)</th>
<th>BMI (kg/m²), mean (SD)</th>
<th>Waist (cm), mean (SD)</th>
<th>Systolic BP (mmHg), mean (SD)</th>
<th>Diastolic BP (mmHg), mean (SD)</th>
<th>Plasma glucose (mmol/L), mean (SD)</th>
<th>Serum lipids (mmol/L), mean (SD)</th>
<th>Family history of, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All</td>
<td>Men (N=377), n (%)</td>
<td>All</td>
<td>Men (N=377), n (%)</td>
<td>All</td>
<td>All</td>
<td>All</td>
<td>All</td>
</tr>
<tr>
<td></td>
<td>43 (14)</td>
<td>24.6 (5.0)</td>
<td>88.8 (13.8)</td>
<td>132.6 (19.3)</td>
<td>80.5 (12.9)</td>
<td>0 min</td>
<td>1.21 (0.33)</td>
<td>Obesity 28 (7.4)</td>
</tr>
<tr>
<td></td>
<td>15 - 24 y</td>
<td>21.6 (4.8)</td>
<td>78 (12.7)</td>
<td>121.7 (11.1)</td>
<td>69.01 (8.4)</td>
<td>4.9 (0.4)</td>
<td>1.25 (0.35)</td>
<td>Raised BP 269 (71.2)</td>
</tr>
<tr>
<td></td>
<td>25 - 34 y</td>
<td>24.84 (5.0)</td>
<td>87.5 (13.6)</td>
<td>128.3 (15.4)</td>
<td>79.1 (10.9)</td>
<td>5.0 (1.1)</td>
<td>1.22 (0.37)</td>
<td>DM 246 (65.3)</td>
</tr>
<tr>
<td></td>
<td>35 - 44 y</td>
<td>25.4 (5.4)</td>
<td>90.5 (13.7)</td>
<td>129.6 (19.1)</td>
<td>82.6 (13.5)</td>
<td>5.9 (2.3)</td>
<td>1.24 (0.88)</td>
<td>MI/stroke 150 (39.8)</td>
</tr>
<tr>
<td></td>
<td>45 - 54 y</td>
<td>25.9 (4.1)</td>
<td>93.1 (10.8)</td>
<td>137.9 (18.3)</td>
<td>85.7 (12.6)</td>
<td>6.5 (2.7)</td>
<td>1.17 (0.25)</td>
<td>Coronary artery disease 164 (43.5)</td>
</tr>
<tr>
<td></td>
<td>55 - 64 y</td>
<td>24.3 (4.9)</td>
<td>90.6 (13.7)</td>
<td>138.5 (22.0)</td>
<td>81.9 (12.0)</td>
<td>6.8 (2.7)</td>
<td>1.25 (0.35)</td>
<td>Peripheral vascular disease 69 (18.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CHF 180 (47.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>45 (12)</td>
<td>29.1 (6.4)</td>
<td>95.4 (15.3)</td>
<td>133.7 (23.4)</td>
<td>81.7 (11.9)</td>
<td>5.4 (1.2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>15 - 24 y</td>
<td>29.1 (6.4)</td>
<td>29.4 (7.6)</td>
<td>82.3 (15.2)</td>
<td>114.5 (12.8)</td>
<td>72.9 (11.6)</td>
<td>4.4 (1.2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>25 - 34 y</td>
<td>24.5 (7.6)</td>
<td>29.4 (7.6)</td>
<td>94.8 (17.3)</td>
<td>121.9 (15.9)</td>
<td>78.8 (11.2)</td>
<td>5.3 (0.9)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>35 - 44 y</td>
<td>24.5 (7.6)</td>
<td>29.5 (6.7)</td>
<td>95.9 (15.2)</td>
<td>129.5 (29.8)</td>
<td>81.9 (11.9)</td>
<td>5.6 (1.0)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45 - 54 y</td>
<td>29.6 (5.4)</td>
<td>29.6 (5.4)</td>
<td>97.2 (14.9)</td>
<td>137.1 (210)</td>
<td>83.4 (12.1)</td>
<td>5.7 (1.2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>55 - 64 y</td>
<td>29.5 (5.9)</td>
<td>29.5 (5.9)</td>
<td>96.9 (13.1)</td>
<td>143.1 (18.9)</td>
<td>83.2 (10.7)</td>
<td>5.8 (1.2)</td>
<td></td>
</tr>
</tbody>
</table>
Table 3. Prevalence of CV and metabolic risk factors in the study group

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>All (N=1378), n (%)</th>
<th>Males (N=377), n (%)</th>
<th>Females (N=1001), n (%)</th>
<th>15 - 24 y (N=131), n (%)</th>
<th>25 - 34 y (N=161), n (%)</th>
<th>35 - 44 y (N=295), n (%)</th>
<th>45 - 54 y (N=423), n (%)</th>
<th>55 - 64 y (N=368), n (%)</th>
<th>p-value*</th>
<th>p-trend†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;25</td>
<td>489 (35.5)</td>
<td>209 (55.4)</td>
<td>280 (27.9)</td>
<td>89 (67.9)</td>
<td>67 (41.2)</td>
<td>94 (31.9)</td>
<td>107 (23.5)</td>
<td>132 (35.8)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>≥25 - &lt;30</td>
<td>442 (32.0)</td>
<td>120 (31.8)</td>
<td>322 (32.1)</td>
<td>22 (16.8)</td>
<td>39 (24.2)</td>
<td>94 (31.9)</td>
<td>165 (39.0)</td>
<td>122 (33.2)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>≥30</td>
<td>447 (32.4)</td>
<td>48 (13.5)</td>
<td>399 (39.9)</td>
<td>20 (15.3)</td>
<td>55 (34.2)</td>
<td>107 (36.3)</td>
<td>151 (35.7)</td>
<td>114 (30.9)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td><strong>Asian cut-points</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>&lt;23</td>
<td>311 (22.5)</td>
<td>149 (39.5)</td>
<td>162 (16.2)</td>
<td>79 (60.3)</td>
<td>47 (29.1)</td>
<td>61 (20.6)</td>
<td>51 (12.1)</td>
<td>73 (19.8)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>≥23.0 - &lt;25</td>
<td>178 (12.9)</td>
<td>60 (15.9)</td>
<td>118 (11.8)</td>
<td>10 (7.6)</td>
<td>20 (12.4)</td>
<td>33 (11.1)</td>
<td>56 (13.2)</td>
<td>59 (16.0)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>≥25</td>
<td>889 (64.5)</td>
<td>168 (44.5)</td>
<td>721 (71.0)</td>
<td>42 (32.1)</td>
<td>94 (57.8)</td>
<td>201 (68.1)</td>
<td>316 (74.7)</td>
<td>236 (64.1)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td><strong>Smoking</strong></td>
<td>344 (24.9)</td>
<td>197 (52.3)</td>
<td>147 (41.4)</td>
<td>&lt;0.001</td>
<td>35 (26.7)</td>
<td>49 (30.4)</td>
<td>67 (22.7)</td>
<td>89 (21.0)</td>
<td>104 (28.2)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>High waist circumference (cm)</strong></td>
<td>1 007 (73.1)</td>
<td>178 (47.2)</td>
<td>829 (82.8)</td>
<td>&lt;0.001</td>
<td>41 (31.3)</td>
<td>100 (62.1)</td>
<td>227 (76.9)</td>
<td>351 (82.9)</td>
<td>288 (78.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Asian phenotype</strong></td>
<td>66 (4.8)</td>
<td>12 (3.1)</td>
<td>54 (5.4)</td>
<td>NS</td>
<td>8 (6.1)</td>
<td>10 (6.2)</td>
<td>13 (4.4)</td>
<td>13 (3.1)</td>
<td>22 (5.9)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>BP ≥140 and ≥90 mmHg</strong></td>
<td>655 (47.5)</td>
<td>154 (40.8)</td>
<td>501 (50.0)</td>
<td>&lt;0.001</td>
<td>8 (6.1)</td>
<td>39 (24.2)</td>
<td>112 (37.9)</td>
<td>237 (56.0)</td>
<td>259 (70.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Prehypertension</strong></td>
<td>236 (17.1)</td>
<td>88 (23.3)</td>
<td>148 (14.8)</td>
<td>&lt;0.001</td>
<td>38 (29.0)</td>
<td>39 (24.2)</td>
<td>21 (7.1)</td>
<td>42 (9.9)</td>
<td>96 (26.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Glycaemic category</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>DM</strong></td>
<td>441 (32.0)</td>
<td>96 (25.5)</td>
<td>345 (34.9)</td>
<td>8 (6.1)</td>
<td>19 (11.8)</td>
<td>78 (26.4)</td>
<td>157 (37.1)</td>
<td>179 (48.6)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td><strong>Diabetes (WHO)</strong></td>
<td>377 (27.4)</td>
<td>81 (21.5)</td>
<td>294 (29.4)</td>
<td>0.003</td>
<td>8 (6.1)</td>
<td>18 (11.2)</td>
<td>66 (22.4)</td>
<td>135 (31.9)</td>
<td>220 (59.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Prediabetes</strong></td>
<td>401 (29.1)</td>
<td>83 (22.0)</td>
<td>318 (31.8)</td>
<td>NS</td>
<td>10 (7.6)</td>
<td>32 (19.9)</td>
<td>80 (27.1)</td>
<td>164 (38.7)</td>
<td>115 (31.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>IFG</strong></td>
<td>198 (14.4)</td>
<td>46 (12.2)</td>
<td>152 (15.1)</td>
<td>0.020</td>
<td>3 (2.3)</td>
<td>8 (4.9)</td>
<td>29 (9.8)</td>
<td>83 (29.6)</td>
<td>75 (20.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>HOMA-IR &gt;2.6</strong></td>
<td>765 (55.5)</td>
<td>155 (41.1)</td>
<td>610 (60.9)</td>
<td>&lt;0.001</td>
<td>48 (36.6)</td>
<td>83 (51.5)</td>
<td>166 (56.2)</td>
<td>249 (58.8)</td>
<td>219 (59.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>TC &gt;5.17 mmol/L</strong></td>
<td>786 (57.0)</td>
<td>218 (57.8)</td>
<td>568 (56.7)</td>
<td>NS</td>
<td>23 (17.6)</td>
<td>71 (44.1)</td>
<td>165 (55.9)</td>
<td>275 (65.0)</td>
<td>252 (68.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>HDL cholesterol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1.03 mmol/L, men</td>
<td>597 (43.3)</td>
<td>116 (30.1)</td>
<td>481 (48.1)</td>
<td>&lt;0.001</td>
<td>46 (35.1)</td>
<td>74 (45.9)</td>
<td>151 (51.1)</td>
<td>182 (43.0)</td>
<td>144 (39.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>&lt;1.29 mmol/L, women</td>
<td>582 (42.2)</td>
<td>170 (45.1)</td>
<td>412 (41.2)</td>
<td>NS</td>
<td>17 (12.9)</td>
<td>44 (27.3)</td>
<td>115 (38.9)</td>
<td>208 (49.1)</td>
<td>198 (53.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Tg &gt;1.69 mmol/L</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LDL cholesterol &gt;2.59 mmol/L</strong></td>
<td>327 (23.7)</td>
<td>62 (16.4)</td>
<td>265 (26.5)</td>
<td>0.047</td>
<td>6 (4.5)</td>
<td>13 (8.1)</td>
<td>61 (20.7)</td>
<td>115 (27.2)</td>
<td>132 (35.9)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Diabetes + dyslipidaemia</strong></td>
<td>61 (4.4)</td>
<td>25 (6.6)</td>
<td>36 (3.6)</td>
<td>&lt;0.001</td>
<td>1 (0.8)</td>
<td>4 (2.5)</td>
<td>12 (4.1)</td>
<td>22 (5.2)</td>
<td>22 (5.9)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*Asian cut-points = modified criteria for Asian Indians;[8] Waist circumference = International Diabetes Federation criteria (men >90 cm, women >80 cm); Asian phenotype = BMI <23 kg/m² and increased waist circumference (men >90 cm, women >80 cm; Prediabetes = IFG or IGT; IFG ≥5.6 - <7.0 mmol/L; TC = serum total cholesterol; Tg = serum total triglyceride; Prehypertension = systolic blood pressure 130 - 139 mmHg or diastolic blood pressure 80 - 89 mmHg; Diabetes + dyslipidaemia = combination of DM + low HDL cholesterol (men <1.03 mmol/L, women <1.29 mmol/L) + TC >5.17 mmol/L + LDL cholesterol >2.59 mmol/L; NS = p-value not statistically significant.

* p values v. males.
† p-value comparison between age groups.
of interest, almost a third of the participants (32.1%) in the 25 - 34-year age groups were also obese. Isolated abdominal obesity using the Asian cut-points for waist circumference and a normal BMI (the 'Asian phenotype') was recorded in only 4.8% of the sample.

Almost half (47.5%) of the total group had hypertension, with the prevalence higher in women than in men (p<0.001) and increasing with age (p<0.001); the peak prevalence was in the oldest age groups. Prehypertension was found in 17.1% (n=236) of participants, and was more common in men than in women.

The crude prevalence of DM, including subjects who self-reported, was 32.0%; the prevalence using WHO criteria was 27.4% (age-adjusted 20.1%), being higher in women (p<0.001) and with advancing age (p-trend <0.001). Prediabetes (IFG or IGT) was found in 29.1% of individuals (age-adjusted 17.6%) and IFG in 14.4% (age-adjusted 8.0%); the prevalence of impaired fasting glucose was also higher with advancing age (p-trend <0.001), with a peak in the 55 - 64-year age group. Insulin resistance (HOMA-IR) was found in 55.5% of participants (age-adjusted 49.6%); surprisingly, 36.6% (age-adjusted 28.2%) of the participants in the youngest age group (15 - 24 years) were also so classified (Table 3).

Hypercholesterolaemia was found in 57.0% of subjects, hypertriglyceridaemia in 42.2% and raised LDL cholesterol in 23.7%. A low concentration of HDL cholesterol was found in 43.3% of subjects, especially in women (48.1%) as opposed to men (30.1%). Of note is that even in the 15 - 24-year age group, 12.9% had elevated triglyceridaemia in 42.2% and raised LDL cholesterol in 23.7%.

Age, total serum cholesterol, serum triglyceride, HDL cholesterol, BMI, blood pressure, smoking and HOMA values were used in a bivariate analysis for DM and hypertension. The BMI, blood pressure, smoking and HOMA values were not reported, was 32.0%; the prevalence using WHO criteria was 27.4% (age-adjusted 20.1%), being higher in women (p<0.001) and with advancing age (p-trend <0.001). Prediabetes (IFG or IGT) was found in 29.1% of individuals (age-adjusted 17.6%) and IFG in 14.4% (age-adjusted 8.0%); the prevalence of impaired fasting glucose was also higher with advancing age (p-trend <0.001), with a peak in the 55 - 64-year age group. Insulin resistance (HOMA-IR) was found in 55.5% of participants (age-adjusted 49.6%); surprisingly, 36.6% (age-adjusted 28.2%) of the participants in the youngest age group (15 - 24 years) were also so classified (Table 3).

Hypercholesterolaemia was found in 57.0% of subjects, hypertriglyceridaemia in 42.2% and raised LDL cholesterol in 23.7%. A low concentration of HDL cholesterol was found in 43.3% of subjects, especially in women (48.1%) as opposed to men (30.1%).

Table 4. Logistic regression model for risk factors associated with diabetes mellitus and hypertension

<table>
<thead>
<tr>
<th>Variable</th>
<th>B</th>
<th>Wald</th>
<th>p-value</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waist (cm)</td>
<td>0.016</td>
<td>12.8</td>
<td>&lt;0.001</td>
<td>1.02</td>
<td>1.007 - 1.026</td>
</tr>
<tr>
<td>Tg (mmol/L)</td>
<td>0.574</td>
<td>61.1</td>
<td>&lt;0.001</td>
<td>1.80</td>
<td>1.11 - 2.59</td>
</tr>
<tr>
<td>Age</td>
<td>0.02</td>
<td>5.125</td>
<td>&lt;0.005</td>
<td>1.06</td>
<td>1.044 - 1.070</td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waist (cm)</td>
<td>0.037</td>
<td>60</td>
<td>&lt;0.001</td>
<td>1.04</td>
<td>1.03 - 1.047</td>
</tr>
<tr>
<td>FBG (mmol/L)</td>
<td>0.017</td>
<td>20.8</td>
<td>&lt;0.001</td>
<td>1.02</td>
<td>1.00 - 1.04</td>
</tr>
<tr>
<td>Tg (mmol/L)</td>
<td>0.162</td>
<td>8.028</td>
<td>0.05</td>
<td>1.18</td>
<td>1.01 - 1.4</td>
</tr>
<tr>
<td>Age</td>
<td>0.070</td>
<td>133</td>
<td>&lt;0.001</td>
<td>1.07</td>
<td>1.06 - 1.086</td>
</tr>
</tbody>
</table>

**Discussion**

This is the first study of SA Indians to document an extremely high CV risk factor prevalence, and it highlights the evolving epidemic of CV risk in teenagers and young adults in this population. Asian Indians across the diaspora are known to have high CV risk.[15] A previous diabetes epidemiology study reported over 20 years ago in the greater Durban area showed lower prevalences of hypertension (14%) and DM (13%).[10] Our study shows that the magnitude of change over two decades has been of epidemic proportions in subjects with similar environmental exposure.

The prevalences of hypertension (47.5%) and DM (age-standardised 20.1%), in particular, are also strikingly high when compared with other population groups in SA. Stewart et al.[16] reported a 33% prevalence of hypertension and a 5% prevalence of DM in their Soweto cohort (black African), with a 28% prevalence of DM in the coloured community.[15]

Furthermore, the high number of participants who were currently smoking, particularly in the youngest age group, is concerning since these individuals already had multiple risk factors in the presence of smoking, which is known to exert a detrimental multiplicative effect on CV risk.[14]

Our study shows a high prevalence of hypercholesterolaemia (57%), raised triglyceride levels (42.2%), raised LDL cholesterol levels (23.7%) and low HDL cholesterol levels (43.3%). The low HDL cholesterol and raised triglyceride levels are in keeping with the characteristic dyslipidaemia pattern seen in Asian Indians, which together with the ‘thin-fat Asian phenotype’ (low BMI and raised waist circumference) is thought to contribute to the development of excess CVD in this population group.[17] Our findings are in direct contrast to this concept, since most of our subjects had generalised (both abdominal and total body) obesity. This, together with the emergence of multiple CV risk factors, including atherogenic dyslipidaemia, in the younger age group, predicts early onset of coronary heart disease[41] and is likely to impose a greater burden of CV disease in the near future, as these individuals reach adulthood.

**Study strengths and limitations**

The study is limited by its cross-sectional design, which rendered us unable to observe or to report on trends associated with CV events that could have developed over time. Another limitation was the low response rates of male participants, which means that the data on men should be interpreted with caution; however, this has been reported in other SA population studies.[14,15] In addition, limited participation was noted in the younger age groups, introducing a potential selection bias for non-working participants. The strength of this study is that it was a population-based study that also included a small sample of younger individuals and was able to show that CV risk was significantly high in this age group.

**Conclusion**

The extremely high prevalence of risk factors in our study explains the emergence of premature coronary heart disease in the community studied and calls for urgent and aggressive intervention measures aimed at diet, physical activity and cessation of smoking at school-going level. A longitudinal follow-up study of these participants to ascertain the degree of CV risk associated with the marked changes in phenotype is urgently required.
Acknowledgements. We thank our participants from the Phoenix community.

Sources of support. This research was made possible in part by a grant from the WHO (Africa Division) and financial support from Servier and Pfizer laboratories. We also wish to acknowledge General Motors (SA) for use of their bus to transport our participants.

Disclaimer. The views expressed in this article are the authors’ own and not the official position of the Durban University of Technology or the University of KwaZulu-Natal or the funders.

References

Accepted 16 November 2015.